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Amino acids are required for activation of the
mammalian target of rapamycin (mTOR) kinase
which regulates protein translation, cell growth, and
autophagy. Cell surface transporters that allow
amino acids to enter the cell and signal to mTOR
are unknown. We show that cellular uptake of
L-glutamine and its subsequent rapid efflux in the
presence of essential amino acids (EAA) is the rate-
limiting step that activates mTOR. L-glutamine
uptake is regulated by SLC1A5 and loss of SLC1A5
function inhibits cell growth and activates autoph-
agy. The molecular basis for L-glutamine sensitivity
is due to SLC7A5/SLC3A2, a bidirectional transporter
that regulates the simultaneous efflux of L-glutamine
out of cells and transport of L-leucine/EAA into cells.
Certain tumor cell lines with high basal cellular levels
of L-glutamine bypass the need for L-glutamine
uptake and are primed for mTOR activation. Thus,
L-glutamine flux regulatesmTOR, translation and au-
tophagy to coordinate cell growth and proliferation.
INTRODUCTION
The target of rapamycin (TOR) Ser/Thr kinase has been
conserved throughout eukaryotic evolution to mediate cellular
responses to extracellular amino acids and growth factors
(Huang and Manning, 2008; Wullschleger et al., 2006). In an
amino acid-rich environment TOR is active and regulates protein
translation but also inhibits macroautophagy (hereafter referred
to as autophagy). When extracellular amino acids are limiting,
autophagy recycles intracellular constituents as a way to provide
an alternative source of amino acids (Mizushima et al., 2008).
Studies using S. cerevisiae provided key insight into the role ofTOR as a signal integrator for amino acids. For example, rapa-
mycin, an inhibitor of TOR, mimics the effect that amino acid
starvation has on protein translation, cell cycle arrest, ribosome
biogenesis and autophagy (Crespo and Hall, 2002). TOR activity
is particularly sensitive to availability of preferred nitrogen sour-
ces such as L-glutamine or L-asparagine such that in their
absence, permeases required for uptake of these amino acids
are downregulated and genes required for the utilization of alter-
native nitrogen sources such as urea and ammonia are upregu-
lated (Cardenas et al., 1999; Hardwick et al., 1999). TOR controls
this metabolic switch by regulating the cellular distribution of
transcription factors (Gln3 and Rtg1/Rtg2) required for
nitrogen-dependent growth (Crespo and Hall, 2002). Nitrogen
starvation is also known to activate autophagy in S. cerevisiae
(Takeshige et al., 1992) consistent with TOR functioning as
a suppressor of autophagy. How L-glutamine regulates TOR
activity is currently unclear.
In all eukaryotes studied to date TOR is partitioned into at least
two distinct signaling complexes (Wullschleger et al., 2006).
In mammalian cells the rapamycin-sensitive mTOR complex
(mTORC) 1 is essential for the phosphorylation and activation
of the 70 kDa ribosomal protein S6 kinase (S6K) 1 and 2. S6K1
directly impacts cell growth by regulating the pioneer round of
protein translation and the eukaryotic initiation factor 3 (eIF3)
translation complex (Holz et al., 2005; Ma et al., 2008). mTORC1
also controls the translation of 50 capped mRNAs by directly
phosphorylating and inhibiting the eukaryotic translation initia-
tion factor 4E (eIF4E) binding protein (4EBP1) resulting in its
dissociation from eIF4E (Gingras et al., 2004). mTORC2 is insen-
sitive to rapamycin, regulates activation of the AKT Ser/Thr
kinase, and can alter the actin cytoskeleton (Jacinto et al.,
2004; Sarbassov et al., 2004, 2005).
Two key growth factor signals that regulate the mTORC1
pathway emanate from the insulin/insulin-like growth factor
(IGF) 1/phosphatidyl inositol-3-OH kinase (PI(3)K) and extra-
cellular signal regulated kinase-p90 ribosomal protein S6 kinase
(ERK-RSK) pathways (Huang and Manning, 2008). TheseCell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc. 521
pathways converge on proteins encoded by the TSC1 and TSC2
tumor suppressor genes which are mutated in the tuberous scle-
rosis complex (TSC) tumor syndrome (Crino et al., 2006). TSC1
and TSC2 proteins physically associate and suppress the RAS
homolog enriched in brain (Rheb), a small G protein required
for mTORC1 activation. The TSC1/TSC2 protein complex can
be phosphorylated and thereby inactivated by PI(3)K and ERK-
RSK signaling (Anjum and Blenis, 2008) allowing Rheb to acti-
vate mTORC1. In the absence of amino acids, growth factor
signals have little or no impact on mTORC1 signaling (Hara
et al., 1998) indicating the presence of a key gating mechanism
upstream of mTOR. Essential amino acids (EAA) such as
L-leucine, L-tryptophan, L-phenylalanine and L-arginine activate
the mTORC1 pathway (Blommaart et al., 1995; Hara et al., 1998;
Wang et al., 1998). Recent observations indicate that Rag
GTPases can physically interact with mTORC1 and regulate its
sub-cellular redistribution in response to L-leucine (Sancak
et al., 2008). How amino acids enter the cell to regulate mTORC1
activation is currently unknown.
In the present study we identify the mechanism by which
L-glutamine exerts control over mTOR signaling. Cellular uptake
of L-glutamine is the rate limiting step for EAA- and growth
factor-regulation of mTORC1. Following uptake, L-glutamine is
effluxed within 1–2 min of adding EAA to cells, leading to recip-
rocal uptake of L-leucine and rapid activation of S6K1. Solute
carrier family 1 member 5 (SLC1A5) is a high affinity L-glutamine
transporter and its inhibition blocks uptake of L-glutamine
leading to inhibition of mTORC1 signaling and activation of au-
tophagy. Solute carrier family 7 member 5 (SLC7A5)/SLC3A2 is
a heterodimeric bidirectional antiporter that regulates the
exchange of intracellular L-glutamine for extracellular L-leucine.
Together these data show that the counter transport of L-gluta-
mine and EAA controls mTORC1 and autophagy.
RESULTS
L-Glutamine Is Required for Rapamycin-Sensitive
mTOR Signaling
mTORC1 signaling is inhibited after growth factor and amino
acid deprivation. Addition of serum-free DMEM to starved
HeLa cells re-activates S6K1 and results in the phosphorylation
of S6K1 (causing an SDS-PAGE mobility shift) as well as ribo-
somal protein S6, a key downstream target of S6K1 (Figure 1A).
In contrast, incubating cells with EAA at the same concentration
found in DMEM does not regulate S6K1 indicating that a compo-
nent present in DMEM is required for mTORC1 activation. The
remaining components found in DMEM include sodium pyru-
vate, sodium bicarbonate, ferric nitrate, nonessential amino
acids (NEAA) and L-glutamine. Using an in-cell western phos-
pho-S6 assay (Figure S1A available with this article online) we
observed that adding sodium pyruvate, sodium bicarbonate,
ferric nitrate or NEAA to EAA does not reconstitute the effect of
DMEM on mTORC1 activation (data not shown and see below).
In contrast, the addition of L-glutamine to EAA upregulates rapa-
mycin-sensitive mTOR-S6K-S6 signaling (Figures 1B, 1E, and
S1). Importantly, L-glutamine and EAA alone have little effect
but together they synergize to activate mTOR (Figure 1B).
Maximal effects occur with 1 mM L-glutamine, comparable to522 Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc.circulating levels which range from 0.5 to 0.7 mM (Dechelotte
et al., 1991; Mittendorfer et al., 2001). To determine if L-gluta-
mine in DMEM is responsible for activating the mTOR pathway,
DMEM lacking this amino acid was added to starved cells.
Remarkably, despite the presence of EAA and other nutrients
in L-glutamine-free medium, regulated S6 phosphorylation is
reduced by 85% (Figure 1C). The effect of L-glutamine on
mTORC1 is also stereoselective (Figure 1D). Since DMEM
contains 4.5 g/L D-glucose and the starvation and stimulation
solutions contain 1 g/L, we confirmed that this variation was
not contributing to the inability of EAA to regulate mTORC1-
S6K1 activation (Figure S1B). The phosphorylation of 4EBP1
and subsequent recruitment of the eukaryotic translation initia-
tion factor 4G (eIF4G) to the eIF4E cap complex is also sensitive
to L-glutamine (Figure 1F, compare lanes 3 and 4). These obser-
vations in HeLa cells extend to other mammalian cell lines in
which rapamycin-sensitive mTOR activity depends on L-gluta-
mine (Figure S2) as well as in S2Drosophila cells (Figure 1G) indi-
cating that this is an evolutionarily conserved process.
L-Glutamine Is Rate Limiting for mTORC1 Activation
To understand the relationship between EAA and L-glutamine,
starved HeLa cells were treated with L-glutamine for 60 min (pre-
load), extracellular L-glutamine washed away and then EAA was
added for different times (Figure 2A). Under these conditions
S6K1 activation kinetics are significantly accelerated compared
to the simultaneous addition of EAA and L-glutamine where
phosphorylation of S6K1 is observed after 60 min (Figure 2A).
Pretreating starved cells with EAA and then L-glutamine does
not activate S6K1 (Figure 2B), confirming that L-glutamine is
upstream of the EAA input. These observations reveal that
L-glutamine is rate limiting for EAA-mediated activation of
S6K1. We next evaluated whether L-glutamine is required for
integrating growth factor signals upstream of mTORC1.
Insulin-regulated activation of AKT and EGF-regulated activa-
tion of ERK1/2 is not affected by L-glutamine pretreatment
(Figure 2C). However, pretreating with L-glutamine sensitizes
S6K1 to insulin and EGF indicating an important role in signal
integration. (Figure 2C).
Although pretreating cells with L-glutamine supports robust
S6K1 phosphorylation within minutes of adding EAA (Figures
2A–2C), S6K1 activation subsides around 60 min (Figure 2A).
Cells treated in this way exhibit transient S6K1 activation
compared to cells treated with EAA and L-glutamine together
where S6K1 phosphorylation persists for several hours (Figures
2D and S3A). Interestingly, addition of L-glutamine after 3 hr re-
activates S6K1 (Figure S3A) indicating that the transient acti-
vation kinetics are due to L-glutamine limitation rather than
consumption of EAA or pathway desensitization. In certain tumor
cell lines L-glutamine can enhance metabolic flux via the process
of glutaminolysis which generates tricarboxylic acid (TCA) cycle
intermediates (DeBerardinis et al., 2007; Kovacevic and Morris,
1972). In order to determine if the L-glutamine effect on S6K1
is due to increasing cellular energy we asked if L-glutamic acid
and a-ketoglutarate (products of glutaminolysis) can sensitize
mTOR to EAA. In contrast to L-glutamine, L-glutamic acid and
a-ketoglutarate are unable to regulate S6K1 activation (Fig-




Figure 1. Glutamine-Dependent Regulation of mTORC1 Effector Signaling
(A) HeLa cells deprived of growth factors and nutrients (starve) were treated with DMEM or EAA for 60 min. The phosphorylation of S6K1Thr389 and S6Ser235/236 and
S6240/244, and total levels of S6K1 (70 kDa cytoplasmic and 85 kDa nuclear isoforms are indicated) were assessed using western blotting.
(B) HeLa cells were starved as in (A) and then treated with the indicated concentrations of EAA and/or L-glutamine for 60 min. EAA concentration (x-fold) was
based on final concentration in DMEM (13). Phosphorylation of S6Ser235/236 was quantitated using the in-cell western assay and expressed as fold-increase
compared to starved cells.
(C) Starved HeLa cells were incubated with DMEM or L-glutamine-deficient DMEM (DMEM-GLN) for 60 min and the phosphorylation of S6Ser235/236 was quan-
titated.
(D) Starved HeLa cells were treated for 60 min as indicated and the phosphorylation of S6Ser235/236 was quantitated. 1 mM L- or D-glutamine was used.
(E) Starved HeLa cells were treated as indicated and the phosphorylation of S6K1Thr389 was quantitated as described in the supplement.
(F) Starved HeLa cells were treated as indicated for 60 min and levels of 4EBP1 and eIF4G associated with m7GTP beads analyzed using western blotting.
(G) S2 or S2-R Drosophila cells starved of serum and amino acids were then treated with amino acids in the presence or absence of L-glutamine.
Data shown are representative of three independent experiments. Data with error bars represent mean ± SD.certain NEAAs such as L-asparagine and L-arginine. NEAAs are
unable to regulate the activation of S6K1 either in pretreatment
mode (Figure 2F) or when added in combination with EAA and/
or L-glutamine (Figure 2G). Taken together, these data show
that L-glutamine-regulated activation of mTOR-S6K1-S6 is
a proximal event and is not derived from increased glutaminoly-
sis and/or NEAA synthesis.
Inhibition of SLC1A5 and SLC7A5/SLC3A2
Antagonizes mTORC1
We sought to identify a molecular mechanism that could explain
why L-glutamine is rate-limiting for mTORC1 activation. L-gluta-
mine influx into mammalian cells can be regulated by at least fourdifferent transporters; Na+-dependent systems A, ASC, N, and
the Na+-independent system L, comprised of low affinity L-gluta-
mine transporters (McGivan and Bungard, 2007). Intriguingly,
a relationship between SLC1A5 (also known as ASCT2) and
SLC7A5 (also known as LAT1) has been proposed (Verrey,
2003) which explains the interplay between L-glutamine and
EAA upstream of mTORC1 (Figures 2A–2C). SLC1A5 is a high-
affinity, Na+-dependent transporter for L-glutamine (Utsuno-
miya-Tate et al., 1996). SLC7A5 transports branched side-chain
amino acids such as L-leucine into cells in exchange for the
efflux of intracellular amino acids such as L-glutamine (Meier
et al., 2002; Yanagida et al., 2001). SLC7A5 functions as part






Figure 2. L-Glutamine Integrates EAA and Growth Factor Signaling to mTORC1 and Regulates the Temporal Dynamics of S6K1
(A) Starved HeLa cells were preincubated with L-glutamine (GLN preload) or starve medium () for 1 hr prior to adding EAA or EAA/GLN for the times indicated.
Phosphorylation of S6K1 was analyzed by western blotting.
(B) Cells were pretreated with either L-glutamine (G) or EAA (E) for 1 hr and incubated with EAA, L-glutamine or EAA/GLN for 15 min prior to lysis.
(C) Cells were treated as in (A) except that insulin (100 nM) or EGF (25 ng/mL) were included as indicated.
(D) Cells pretreated with either L-glutamine or starve medium for 1 hr were then incubated with EAA or EAA/GLN, respectively, for the indicated times.
(E) Cells pretreated for 1 hr with 10 mM L-glutamine, L-glutamic acid (GLU) or a-ketoglutaric acid (aKG), were washed and then incubated with starve or
EAA-containing medium for 15 min.
(F) Cells pretreated with either 10 mM L-glutamine or 13 nonessential amino acids (NEAA) for 1 hr, were washed and then incubated with starve or EAA-containing
medium for 15 min.
(G) Starved HeLa cells were treated as indicated for 1 hr and lysed.
All data is representative of at least three independent experiments.resides at the plasma membrane (Mastroberardino et al., 1998).
Thus, we hypothesized that intracellular L-glutamine, trans-
ported into the cell by SLC1A5, serves as an efflux substrate
for SLC7A5/SLC3A2 allowing for the counter transport of EAA.
L-g-glutamyl-p-nitroanilide (GPNA), an inhibitor of SLC1A5-
regulated transport (Esslinger et al., 2005) dose-dependently
inhibits S6 phosphorylation and the eIF4E cap complex524 Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc.(Figures 3A and 3B). To evaluate the specificity of GPNA in sup-
pressing the L-glutamine input, cells were pretreated with L-
glutamine in the presence or absence of GPNA for 60 min, and
then exposed to EAA in the presence or absence of GPNA for
15 min (Figure 3C). The presence of GPNA during the pretreat-
ment period, but not with EAA, completely inhibits S6K1 activa-








Figure 3. Pharmacological Modulation of SLC1A5 and SLC7A5 Inhibits mTOR Regulation
(A) Starved HeLa cells were treated as indicated in the presence of increasing concentrations of GPNA (1 hr).
(B) Starved cells were treated for 60 min and the cap translation complex analyzed. 10 mM GPNA was used.
(C) Cells were pretreated (preload) for 60 min with L-glutamine in the presence or absence of GPNA prior to treatment with EAA for 15 min in the presence or
absence of GPNA.
(D and E) Starved HeLa cells were treated with EAA containing 1 mM L-glutamine (EAA/GLN) and 100 nM insulin in the absence or presence of BCH for 60 min. A
nonspecific reactive band (*) is indicated.
(F) The phosphorylation of S6Ser235/236 was quantitated following treatment with the indicated concentrations (X) of EAA in the presence of 1 mM L-glutamine and
D-phenylalanine.
(G) Starved HeLa cells were treated as indicated in the presence and absence of 50 mM D-phenylalanine (D-Phe).
(H) Cells were pretreated for 60 min as indicated and then treated with EAA for 15 min in the presence or absence of D-Phe.
Data with error bars represent mean ± SD.SLC1A5 inhibitor GPNA antagonizes mTORC1 signaling by
limiting cellular uptake of L-glutamine.
To interrogate the requirement of SLC7A5/SLC3A2, a candi-
date transporter for EAA, 2-aminobicyclo-(2,2,1)heptane-
carboxylic acid (BCH) was used. BCH, an inhibitor of SLC7A5(Kanai et al., 1998; Mastroberardino et al., 1998; Yanagida
et al., 2001), suppresses S6K-S6 phosphorylation (Figures 3D,
3E, S3B, and S3C). BCH does not inhibit AKT phosphorylation
(Figure 3D) or phorbol 12-myristate 13-acetate (PMA) regulation
of S6 phosphorylation in starved HeLa cells (Figure S3D)Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc. 525
consistent with the ability of RSK to directly phosphorylate S6
in a mTORC1-independent manner (Anjum and Blenis, 2008).
Thus, BCH specifically inhibits the amino acid input to mTORC1.
As an alternative way to modulate SLC7A5/SLC3A2 function,
D-phenylalanine was used. Unlike L-phenylalanine, a high
affinity SLC7A5 substrate which regulates S6K1 activation
(Hara et al., 1998; Kanai et al., 1998; Mastroberardino et al.,
1998; Yanagida et al., 2001), D-phenylalanine inhibits SLC7A5/
SLC3A2-mediated transport (Kanai et al., 1998). D-phenylala-
nine inhibits rapamycin-sensitive S6 phosphorylation (Figure 3F)
and the cap translation complex (Figure 3G). In contrast to the
mode of action of GPNA, D-phenylalanine specifically inhibits
the EAA rather than the L-glutamine input (Figure 3H). Collec-
tively these results show that a BCH- and D-phenylalanine sensi-
tive activity is responsible for EAA regulation of mTORC1 and are
consistent with previous studies showing that they inhibit the
bidirectional transporter SLC7A5/SLC3A2.
Efflux of L-Glutamine and Uptake of L-Leucine
Precede S6K1 Activation
The above data supports a model in which SLC1A5-mediated
uptake of L-glutamine provides a signal for EAA to regulate
mTOR signaling. Since SLC7A5/SLC3A2 is capable of using
L-glutamine as an efflux substrate (Meier et al., 2002; Yanagida
et al., 2001), we tested the hypothesis that EAA regulates the
efflux of intracellular L-glutamine by quantifying its presence in
medium after EAA treatment. Starved cells were pretreated
with L-glutamine for 1 hr and washed as described above
(Figure 2A). After treating with EAA for 15 min, conditioned
medium was collected and transferred to naive starved cells
(Figure 4A, lane 3). This conditioned medium supports activation
of S6K1 though not to the extent as direct addition of EAA to
L-glutamine-preloaded cells (Figure 4A, compare lanes 3 and
6). Conditioned medium taken from EAA-treated, nonprimed
cells does not activate S6K1 (Figure 4A, lane 5) proving that
the effect of conditioned medium is dependent on L-glutamine.
These results indicate that a cellular factor, likely L-glutamine,
is released in the presence of EAA and which is capable of regu-
lating mTOR-S6K1 activity. This factor is released after only
2.5 min in the presence of EAA (Figure 4B).
To prove that L-glutamine is effluxed out of the cell in res-
ponse to EAA treatment, conditioned medium was analyzed
using HPLC–triple quadruple mass spectrometry (LC/MS/MS).
L-glutamine is undetectable in conditioned medium taken from
cells treated with EAA for 2.5 min (Figure 4C, left trace) however,
a 10-fold increase in L-glutamine concentration is detected in
conditioned medium taken from L-glutamine primed-EAA treated
cells compared to control cells (Figure 4C and 4E). The absolute
concentration of L-glutamine in this medium was approximately
100-fold lower than that required to maximally regulate mTORC1
pathway activity (Figure 1) consistent with the submaximal effect
associated with conditioned medium in naive cells (Figure 4A).
Using a stable-isotope labeled L-glutamine analog we observed
that efflux of L-glutamine with time correlates with depletion of
cellular L-glutamine (Figure 4D). Importantly, insulin treatment
does not lead to L-glutamine efflux indicating that the above
effects are specific to EAA (Figure 4E). These observations prove
that L-glutamine is rapidly effluxed out of the cell in response to526 Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc.EAA. If SLC7A5/SLC3A2 regulates exchange of L-glutamine for
EAA then L-glutamine should enhance the uptake of L-leucine.
Indeed, by using labeled L-glutamine and L-leucine analogs,
reciprocal exchange of these amino acids takes place
(Figure 4F). L-glutamic acid is not capable of regulating L-leucine
uptake (Figure 4G) and unlike L-glutamine, its cellular levels are
not depleted following treatment with EAA (Fig. S5A and B).
This provides clear evidence that L-glutamine metabolites are
not involved in mTORC1 activation. Finally, uptake of labeled
L-glutamine into cells is inhibited by GPNA (Figure 4H) and both
basal and L-glutamine-regulated L-leucine uptake is inhibited
by BCH and D-phenylalanine (Figure 4I).
SLC1A5 and SLC7A5/SLC3A2 Are Required for Amino
Acid Exchange, mTORC1 Signaling and Cell Growth
To determine if SLC1A5 and SLC7A5/SLC3A2 are required for
amino acid-regulation of mTORC1, we identified two siRNAs
for each gene that knocked-down the target mRNA by 80%–
90% (Figures S4A–S4C). As expected, amino acid regulation of
S6 phosphorylation is inhibited with mTOR siRNA and increased
with TSC2 siRNA (Figure 5A). Each of the SLC-targeted siRNAs
inhibit S6-S6K1 phosphorylation similarly to the mTOR siRNA
(Figures 5A and 5B). Next, we examined the effect of these
RNAi reagents on regulation of the cap complex. As expected,
downregulation of mTOR prevents dissociation of 4EBP1 from
the eIF4E cap complex and even enhances basal 4EBP1 associ-
ation (Figure 5C, compare lanes 2 and 4, 1 and 3). Knockdown of
either SLC1A5, SLC7A5 or SLC3A2 also enhances basal associ-
ation of 4EBP1 with the cap complex and restores 4EBP1 to
the complex in the presence of L-glutamine and EAA
(Figure 5C, compare lanes 2, 6, 8, and 10). Similar effects occur
in asynchronously cycling, serum starved or insulin-treated cells
(Figure S4D). Following downregulation of SLC3A2, eIF4G
recruitment was not inhibited by BCH (Figure S3E) confirming
that BCH targets SLC7A5/SLC3A2. Note that expression of
SLC3A2 and SLC7A5 is codependent (Mastroberardino et al.,
1998) explaining the decreased expression of SLC3A2 and
SLC7A5 when either is targeted with RNAi (Figure 5C and
S4D). L-glutamine uptake is significantly reduced when
SLC1A5 is downregulated resulting in decreased efflux after
adding EAA (Figure 5D). Downregulation of SLC3A2 or SLC7A5
blocks L-glutamine-regulated uptake of L-leucine (Figure 5E).
These data prove that SLC1A5 and SLC7A5/SLC3A2 support
amino acid exchange in HeLa cells and that this is required for
activation of mTORC1.
The ability of mTOR to regulate translation is responsible for
cellular and organismal growth (Arsham and Neufeld, 2006).
We therefore quantitated relative cell size after downregulation
of SLC1A5, SLC7A5 or SLC3A2. Compared to a nonsilencing
siRNA, downregulation of mTOR results in approximately 10%
reduction in cell size (Figures 5F and 5G) consistent with previous
reports in mammalian cells (Fingar et al., 2002; Kim et al.,
2002). For control purposes TSC2 downregulation was used to
show that under these experimental conditions HeLa cells can
also grow in size (Figure S6A). Transfection with SLC1A5,
SLC3A2 or SLC7A5 siRNAs reduces cell size 10%–20% below
that of control transfected cells (Figures 5F, 5G, and S6A). Two






Figure 4. Bidirectional Transport of L-Glutamine and EAA Is Upstream of mTOR Activation
(A) Starved cells were preincubated with L-glutamine or starve medium () for 1 hr prior to adding EAA or starve medium (15 min). Conditioned medium (CM) was
removed and added to naive starved cells for 1 hr (lanes 1–5) and S6K1 phosphorylation analyzed. Phosphorylation of S6K1 in an extract from EAA-treated
L-glutamine primed cells is shown (lane 6).
(B) Conditioned medium was prepared as in (A) except collection was 2.5, 5, 10, and 15 min after adding EAA.
(C) LC/MS/MS ion chromatograms of L-glutamine in conditioned medium taken at 2.5 min from cells pretreated with starve medium (PBS) prior to EAA (left trace),
pretreated with L-glutamine prior to PBS (middle trace) or pretreated with L-glutamine prior to EAA (right trace).
(D) Starved HeLa cells were pretreated with labeled L-glutamine for 1 hr, washed, and then treated with EAA containing 0.4 mM labeled L-leucine (L-Leu/EAA) for
various times (minutes). The absolute levels of labeled L-glutamine in conditioned medium (black symbols) and cell extracts (red symbols) was quantitated using
LC/MS/MS.
(E) Starved cells were treated as in (C) and the L-glutamine efflux (fold-change in medium concentration) after treatment with PBS, EAA or insulin for 2.5 min
quantitated.
(F) Cells were treated as in (D) and after 2.5 min the absolute levels of effluxed labeled L-glutamine (black) and labeled L-leucine in cells (red) was quantitated.
(G) Cells pretreated with 10 mM labeled L-glutamine or labeled L-glutamic acid for 1 hr were washed, treated with EAA containing labeled L-leucine for 2.5 min
and extracted.
(H) Starved cells were treated with labeled L-glutamine for 1 hr in the absence or presence of 10 mM GPNA. The absolute levels of L-glutamine in cell extracts
were quantitated.
(I) Cells were treated with labeled L-glutamine for 1 hr, washed and incubated with 0.4 mM labeled L-leucine in the absence and presence of BCH or D-Phe for
2.5 min.
Data with error bars represent mean ± SD.size phenotypes were due to (1) mTOR pathway-specific inhibi-
tion and (2) on-target RNAi. We first determined if downregula-
tion of TSC2 would restore cell growth in the presence of
SLC1A5 or SLC7A5 siRNA. Under this experimental paradigm
downregulation of mTOR suppresses the TSC2 cell growth
phenotype and further reduces cell size when compared to
mock transfected cells (Figure 5H) consistent with mTOR acting
downstream of TSC2. In contrast, downregulation of either
SLC1A5 or SLC7A5 in the presence of TSC2 siRNA results inincreased cell growth (Figure 5H). This indicates that SLC1A5
and SLC7A5 may act upstream of TSC2 to mediate an amino
acid signal to mTOR. It should be noted however that in these
experiments cell growth was not rescued to the same level as
TSC2 downregulation alone (i.e., 75% rescue for SLC1A5 and
50% for SLC7A5). This could be due to incomplete knockdown
of TSC2 or that SLC1A5 and SLC7A5/SLC3A2 can signal to
mTOR independently of TSC2. The later possibility is supported






Figure 5. RNAi-Mediated Downregulation of SLC1A5, SLC3A2, or SLC7A5 Inhibits Amino Acid Transport and mTOR Pathway Activity
(A) HeLa cells transfected with the indicated siRNAs were amino acid starved (open bars) and treated for 60 min with EAA containing 1 mM L-glutamine (red bars).
Phosphorylation of S6Ser235/236 was quantitated using the Delfia readout.
(B) After siRNA transfection (96 hr) S6K1 phosphorylation was analyzed.
(C) Cells transfected with siRNAs were treated as indicated (1 hr) and the cap translation complex analyzed.
(D) Cells transfected with scramble or SLC1A5_1 siRNA were starved and preincubated with labeled L-glutamine (1 hr). Cells were extracted for quantitation of
labeled L-glutamine uptake (open bars) or treated with labeled L-leucine/EAA (2.5 min) for quantitation of effluxed labeled L-glutamine (filled bars).
(E) Cells were transfected with the indicated siRNAs, starved and pretreated with labeled L-glutamine (hatched bars) or starve medium (filled bars) for 1 hr,
washed and then treated with 0.4 mM labeled L-leucine for 2.5 min. Cell extracts were processed for absolute quantitation of L-leucine.
(F) HeLa cells were transfected with siRNAs (nonsilencing, NS) for 72 hr and collected for cell size quantitation.
(G) Cell size data from three independent experiments (mean ± SEM) is shown.
(H)HeLacells were transfected withscramble,mTOR, SLC1A5orSLC7A5siRNAs in the presenceorabsence ofa TSC2siRNA andprocessed forcell sizequantitation.
(I) Vector-expressing (mock) or RNAi-insensitive GFP-SLC1A5-expressing HeLa cells (clones L1 and L2) were transfected with siRNAs and processed for cell size
quantitation.
The data shown (mean ± SD) represent three independent experiments.et al., 2005) as well as present observations that L-glutamine and
EAA significantly increase S6 phosphorylation in cells trans-
fected with TSC2 siRNA (Figure 5A). Finally, cell size phenotypic
rescue experiments were performed to prove that the SLC1A5
RNAi phenotype is on-target. HeLa cells stably expressing
a GFP-SLC1A5 allele insensitive to SLC1A5_1 but not
SLC1A5_2 siRNA were generated (Figure S6B). The reduction
in cell size associated with SLC1A5_1 was completely sup-
pressed in these cells (Figure 5I) proving that the observed528 Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc.phenotypes are due to SLC1A5. Note however that the stable
HeLa clones are still sensitive to the SLC1A5_2 siRNA
(Figure 5I) which downregulates both the exogenous and
endogenous SLC1A5 (Figure S6B).
High Levels of Endogenous L-Glutamine Prime
mTORC1 Activation
Upon screening cell lines for L-glutamine-dependent mTOR
signaling, lines were identified that showed indifference to
Figure 6. Efflux of Endogenous L-Glutamine Regulates S6K1 Activation in MCF7 Cells
(A) MCF7 cells were amino acid starved, treated as indicated (1 hr) and processed for quantitation of S6 phosphorylation.
(B) Starved MCF7 cells were treated with EAA in the absence or presence of 50 mM D-Phe for various times.
(C) Starved MCF7 cells were treated with labeled L-leucine/EAA (filled circles) or starve medium (stars) for various times and conditioned medium processed for
quantitation of L-glutamine.
(D) MCF7 cells were treated as in (C) and extracted at the times indicated for quantitation of L-glutamine (black circles) or labeled L-leucine (red circles).
(E) Starved MCF7 cells were treated as indicated and S6K1 activation analyzed using western blotting.
Data with error bars represent mean ± SD.exogenous L-glutamine. For example, in MCF7 cells EAA alone is
sufficient to regulate D-phenylalanine-sensitive phosphorylation
of S6K1 and S6 (Figures 6A and 6B). Intriguingly, the S6K1 activa-
tion kinetics (Figure 6B) mirror what takes place in L-glutamine
preloaded HeLa cells (Figure 2A) suggesting that MCF7 cells
are primed for the EAA input. Adding EAA to MCF7 cells increases
the medium concentration of L-glutamine 3- to 4-fold (Figure 6C)
indicating that these cells synthesize L-glutamine which can regu-
late uptake of EAA. L-glutamine is readily detected in MCF7 cells
and this rapidly decreases upon treatment with L-leucine/EAA
consistent with its efflux from the cell (Figure 6D). Bidirectional
transport of L-glutamine and labeled L-leucine in MCF7 cells
subsides after 30–60 min (Figures 6C and 6D) in line with S6K1
inactivation (Figure 6B). To determine if the cellular concentration
of L-glutamine is limiting sustained S6K1 activity, exogenous
L-glutamine was added in combination with EAA. Under theseconditions total cellular L-glutamine levels are elevated (data
not shown) and S6K1 is continually activated for up to 2 hr
(Figure 6E). These data illustrate that bidirectional flux of L-gluta-
mine and L-leucine takes place in multiple cells types and reveal
the possibility that certain tumor lines with elevated cellular
L-glutamine levels are primed for EAA-regulation of mTORC1.
L-Glutamine and SLC1A5 Suppress Autophagy
Inhibition of mTOR signaling by withdrawing amino acids or
adding rapamycin activates autophagy (Blommaart et al.,
1995). We hypothesized that the absence of L-glutamine or
downregulation of SLC1A5 would also activate autophagy. To
test this we developed a tandem fluorescent image-based
system (Kimura et al., 2007) to quantitate the redistribution of
the autophagosomal membrane protein LC3. RT112 cells exhibit
L-glutamine-dependent activation of S6K1 (Figure S6C) andCell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc. 529
Figure 7. L-Glutamine and SLC1A5 Regulate Autophagy
(A) Confocal images of mCherry-eGFP-LC3a distribution before (+) and after (-) L-glutamine starvation are shown.
(B) Quantitation of autophagy flux in RT112 cells.
(C) RT112 cells transfected with the individual siRNAs for 72 hr were serum starved for 24 hr and processed for autophagy flux quantitation. Rapamycin was
added to scrambled siRNA transfected cells during the starvation period.
(D) EAA regulation of mTOR signaling, cell growth and suppression of autophagy requires intracellular uptake and subsequent efflux of L-glutamine (SLC3A2
dimerized with SLC7A5 is shown in yellow).
All data (mean ± SD) are representative of at least three independent experiments.were engineered to express mCherry-eGFP-LC3. Since eGFP is
unstable in cellular compartments pH < 6.0, an increase in the
mCherry:eGFP puncta ratio indicates enhanced autophagy flux
and allows discrimination between the distribution of LC3 before
and after lysosomal fusion. In serum-free medium LC3 codistri-
butes into mCherry- and eGFP-positive puncta (Figure 7A,
yellow puncta) but cytoplasmic codistribution of mCherry- and
eGFP-LC3 is also observed indicating that autophagy is not
maximally activated. After removing extracellular L-glutamine,
the cytoplasmic localization disappears and LC3 codistribution
into mCherry- and eGFP-positive puncta is inhibited (Fig-
ure 7A). This indicates a shift of LC3 into acidic, GFP-sensitive530 Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc.compartments such as lysosomes. These effects were quanti-
tated using high content image analysis of individual mCherry
and eGFP LC3 puncta (Figure 7B). As controls, rapamycin and
bafilomycin A were used as activators and inhibitors of autoph-
agy, respectively (Figure 7B). Incubation of cells in serum-free
(L-glutamine-containing) DMEM increases the basal level of au-
tophagy, consistent with the ability of growth factors to regulate
mTOR (Martin and Blenis, 2002). Importantly, incubation with
serum- and L-glutamine-free DMEM results in a much larger
activation of autophagy, almost reaching the level achieved by
rapamycin (Figure 7B). Since EAA are still present in the L-gluta-
mine-free medium this observation proves that L-glutamine is
essential for autophagy suppression and is consistent with the
inability of EAA alone to activate mTOR and suppress autoph-
agy. Finally, downregulation of SLC1A5 using RNAi enhances
autophagy flux to the same extent as rapamycin or mTOR inhibi-
tion (Figures 7C and S6D). These data show that L-glutamine
transport into cells via SLC1A5 is required for suppression of
autophagy.
DISCUSSION
The ability of amino acids to regulate TOR signaling is function-
ally conserved across eukaryotes and is essential for mTORC1
to integrate growth factor signals (Dann and Thomas, 2006).
Presumably amino acid transporters function upstream of
mTORC1 to allow the cell to sense amino acid availability and
launch an anabolic response (increased translation and growth)
or when amino acids are limiting, a catabolic response such as
autophagy. Amino acid transporters that perform such a role
have not been identified. Here we have shown that (1) L-gluta-
mine is an essential and rate-limiting sensitizing factor that
allows EAA and growth factors to activate mTOR, (2) the high
affinity L-glutamine transporter SLC1A5 and the heterodimeric
SLC7A5/SLC3A2 bidirectional transporter are required for amino
acid transport, mTORC1 pathway activity and cell growth, and
(3) L-glutamine and SLC1A5 function are required to suppress
autophagy.
A Two-Step Amino Acid Transport Mechanism
Regulates mTORC1
The findings presented here are consistent with a two-step
process that defines how amino acids activate mTOR
(Figure 7D). First, SLC1A5 regulates an increase in the intracel-
lular concentration of L-glutamine. Second, SLC7A5/SLC3A2
uses intracellular L-glutamine as an efflux substrate to regulate
the uptake of extracellular L-leucine which subsequently leads
to activation of mTORC1. This model is supported by the fact
that SLC7A5/SLC3A2 is an obligate exchanger (Meier et al.,
2002) and amino acid uptake requires an intracellular efflux
substrate such as L-glutamine (Meier et al., 2002; Yanagida
et al., 2001). The finding that reactivation of mTORC1 in starved
cells depends on cellular uptake of L-glutamine is consistent
with its role as an efflux substrate for SLC7A5/SLC3A2. Further-
more, LC/MS/MS analysis identified reciprocal exchange of
intracellular L-glutamine for extracellular L-leucine in mammalian
cells minutes before the activation of S6K1.
Some of the preferred SLC7A5 substrates are known to
contribute to the activation of S6K1 (Hara et al., 1998) consistent
with the observation that BCH and RNAi-mediated suppression
of SLC7A5 inhibited mTORC1 activity and cell growth. Downre-
gulation of SLC3A2 destabilized SLC7A5 which is in line with
reports that cell surface expression of the heterodimer requires
both subunits (Kanai et al., 1998; Mastroberardino et al., 1998).
SLC3A2 can also heterodimerize with other transporters related
to SLC7A5 (Verrey, 2003) such as SLC7A8 (also known as LAT2).
Like SLC7A5, SLC7A8 requires SLC3A2 for proper cellular
distribution and so it is possible that the observations associated
with SLC7A5 or SLC3A2 RNAi could be indirectly mediated via
effects on SLC7A8 expression and/or localization. This is unlikelysince D-phenylalanine, which potently antagonizes mTORC1,
inhibits transport via SLC7A5 but not SLC7A8 (Kanai et al.,
1998; Segawa et al., 1999). Thus, SLC7A5/SLC3A2 is the key
EAA transporter upstream of mTORC1. SLC7A5 is upregulated
in many tumors and cancer cell lines (Fuchs and Bode, 2005;
Wolf et al., 1996; Yanagida et al., 2001) indicating that it may
be involved in supporting the increased anabolic needs of
tumors. Furthermore, SLC7A5 expression is induced by phorbol
esters and PDGF (Liu et al., 2004; Nii et al., 2001) and its 30UTR
contains destabilizing AU-rich elements (Boado et al., 1999;
Gaugitsch et al., 1992), a feature associated with several proto-
oncogene products.
In Drosophila melanogaster, distinct amino acid transporters
known as minidiscs and slimfast orchestrate cellular and organ-
ismal growth (Colombani et al., 2003; Martin et al., 2000). mini-
discs and slimfast function in the fat body to sense nutrient
availability and control body size, the later doing so via dTOR
(Colombani et al., 2003). Interestingly, both transporters have
high homology with members of the SLC7 family with minidiscs
sharing 48% sequence identity specifically with SLC7A5 (Martin
et al., 2000). Together with the present finding that L-glutamine is
required for activation of dS6K in S2 cells, it is likely that bidirec-
tional flux of amino acids has been conserved throughout
eukaryotic evolution to regulate TOR and cell growth.
L-Glutamine Regulates the Temporal Dynamics
of mTORC1-S6K1 Signaling
L-glutamine-mediated sensitization of mTORC1 activation was
sharply dose-dependent suggesting that a rise in intracellular
L-glutamine concentration provides a switch for uptake of EAA
leading to mTORC1 signaling. Preloading cells with L-glutamine
prior to treatment with EAA or growth factors accelerated S6K1
activation indicating that SLC1A5-regulated uptake of L-gluta-
mine is rate-limiting for mTORC1 pathway activation. This
striking observation likely explains the 30-60 min lag that typi-
cally precedes mTOR-S6K1 activation in response to amino
acids and growth factors. Importantly, upon depletion of intra-
cellular L-glutamine, L-leucine uptake stops and mTORC1 is in-
activated. These observations, which were made in several cell
types, lead to the prediction that L-glutamine is required to
sustain mTORC1-S6K1 signals during cell cycle progression.
This is likely to be of fundamental importance since normal prolif-
erative responses require coordination of cell division and
mTOR-dependent control of cell size (Fingar et al., 2002). More-
over, observations made in MCF7 cells raise the possibility that
tumor cell lines with elevated L-glutamine levels are primed for
EAA-regulation of mTORC1 (Figure 7D). One possible mecha-
nism explaining the elevated levels of L-glutamine could be aber-
rant upregulation of glutamine synthetase. Although further
studies will be required to determine under what conditions
this might occur, overexpression of glutamine synthetase in
tumors has been reported (Christa et al., 1994; Gebhardt and
Williams, 1995).
L-Glutamine: At the Center of Cell Growth
and Metabolism
L-glutamine is the most abundant nonessential amino acid and
regulates the proliferation of diverse cell types (Eagle et al.,Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc. 531
1956; Reitzer et al., 1979). Interestingly, skeletal muscle is one of
the richest stores of L-glutamine in the body with intramuscular
concentrations around 20 mM (Mittendorfer et al., 2001) and is
a tissue type that is dependent on mTORC1 for cell growth (Bod-
ine et al., 2001; Ohanna et al., 2005). The demand for L-glutamine
can often exceed the ability of individual cells to synthesize it de
novo rendering it a ‘‘conditionally essential’’ amino acid (Fuchs
and Bode, 2006). This is particularly important in tumor cells
where it has been shown that glutaminolysis is used to replenish
intermediates for the TCA cycle and to generate reductive power
in the form of NADPH (DeBerardinis et al., 2007). Importantly, the
observations made using L-glutamic acid and a-ketoglutarate
provide evidence that glutaminolysis is not contributing to
mTORC1 activation. Instead, our data are consistent with
a model in which intracellular L-glutamine acts upstream of
mTORC1 to regulate EAA uptake by acting as an efflux substrate
for SLC7A5/SLC3A2.
Current models describing how mTORC1 is activated by nutri-
ents show that EAA are required for integration of growth factor
signals (Arsham and Neufeld, 2006; Jacinto and Lorberg, 2008).
The present data suggests an update to these models in recog-
nition of the fact that L-glutamine is rate limiting for mTORC1
activation by EAA and growth factors. Why does L-glutamine
have this critical role? Tissue homeostasis depends on the coor-
dination of protein translation, metabolic flux and nitrogen
balance, processes that depend on L-glutamine. Not surpris-
ingly, tumor cells have an increased demand for L-glutamine
(DeBerardinis et al., 2007) and during cachexia circulating and
skeletal muscle levels of L-glutamine are greatly reduced (Hole-
cek, 2002). As mTORC1 is a major regulator of cell size and
tissue mass in both normal and diseased states (Bodine et al.,
2001; Ohanna et al., 2005; Shaw and Cantley, 2006) it is perhaps
appropriate that its activity is sensitive to both intra-cellular and
circulating levels of L-glutamine.
EXPERIMENTAL PROCEDURES
Mammalian Cell Culture, Treatments, and Extract Preparation
HeLa and MCF7 cells were cultured as described in the supplementary infor-
mation. Amino acid starvation was performed by depriving cells of FBS for
20 hr and then incubation with D-PBS containing CaCL2, MgCl2, 15 mg/L
phenol red, 20 mM HEPES and 1 g/L D-glucose (starve medium) for 3 hr.
Starved cells were cultured with a mixture of EAA at the concentration found
in DMEM (MEM amino acids) in the presence or absence of 1 or 10 mM
L-glutamine. L-glutamic acid, a-ketoglutarate and nonessential amino acids
(NEAA) solution (Sigma, St. Louis, MO) were diluted in starve medium and
the resulting solutions adjusted to pH 7.2. GPNA (gamma-L-glutamyl-p-nitro-
anilide hydrochloride, (MP Biomedicals, Solon, OH) and BCH (2-aminobicyclo-
(2,2,1)-heptane-2-carboxyclic acid, (Sigma, St. Louis, MO) were dissolved in
stimulation medium and pH adjusted to 7.2. For L-glutamine preincubation
experiments, amino acid starved cells were cultured in the presence of
10 mM L-glutamine for 1 hr at 37C. The medium was then removed and
cell monolayers washed twice with starve medium before adding test medium
for the times indicated. Details of cell lysis buffer, Drosophila cell culture and
stimulations, antibodies, eIF4E-cap complex assay and the in-cell western
assay are provided in the supplementary information.
LC/MS/MS Measurement of L-Glutamine and Stable-Isotope
Labeled Amino Acid Analogs
The L-glutamine concentration in culture medium was quantified using
LC/MS/MS with an API4000 triple quadruple MS system (Applied Biosystems532 Cell 136, 521–534, February 6, 2009 ª2009 Elsevier Inc.Inc, Framingham, MA) coupled to an Agilent 1200 HPLC (Santa Clara, CA) and
a Leap CTC Autosampler (Carrboro, NC). LC conditions and stable-isotope
labeled amino acid details are provided in the supplementary information. Cali-
bration standards were prepared in acetonitrile/water solvent mixture (50/50 v/
v) containing 0.5% blank culture medium. Samples of conditioned culture
medium, collected at different time points after incubation with cells, were
diluted 1:200 (v/v) with the acetonitrile/water solvent mixture containing the
internal standard. Diluted samples (5 mL) were injected and analyzed by LC/
MS/MS. For quantitation of L-glutamine and labeled amino acids in cell
extracts, cell monolayers were washed twice with ice-cold PBS, scraped
into PBS (200 mL), snap frozen three times and centrifuged (14,000 rpm,
10 min) to remove cell debris. After sample normalization based on total
protein levels, protein in lysates was removed by precipitation and centrifuga-
tion after the addition of two equivalent aliquots of acetonitrile. Absolute levels
of amino acids in the supernatants were determined as described above for
the medium samples.
RNAi and Cell Size Assays
siRNA sequence information and design of the RNAi-insensitive SLC1A5
cDNA are described in the supplementary information. Final concentration
of siRNA in each experiment was 25 nM. TSC2 or scramble siRNAs were trans-
fected 24 hr prior to transfection with scramble, mTOR, SLC1A5 or SLC7A5
siRNA (Figure 5H). FACS based cell size quantitation was performed as
described previously (Edinger and Thompson, 2002) with specific details
described in the supplementary information.
Quantitation of Autophagy
RT112 cells stably expressing mCherry-eGFP-LC3a were cultured in clear
bottom 384-well plates (24 hr). Cells were re-fed with rich medium (DMEM/
10% FBS), 30 nM rapamycin, 100 nM bafilomycin A, serum free DMEM (con-
taining 4 mM L-glutamine) or serum free DMEM lacking L-glutamine. After
18 hr cells were fixed, stained with Hoechst and LC3a puncta analyzed using
an IN Cell Analyzer 1000 (GE Healthcare, Piscataway, NJ). Each data point
shown in Figures 7B and 7C represents the average of 8 fields of view with
50-100 cells/field. Autophagy flux is calculated based on the mCherry-GFP
puncta intensity ratio and expressed as a percentage of rapamycin-induced
autophagy. Representative images (Figure 7A) were collected using a LSM
510 META confocal microscope (Carl Zeiss MicroImaging, Inc, Thornwood,
NY).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and six
figures and can be found with this article online at http://www.cell.com/
supplemental/S0092-8674(08)01519-5.
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